Zacks Research Forecasts Integer’s Q3 Earnings (NYSE:ITGR)

Integer Holdings Corporation (NYSE:ITGR) – Zacks Research lowered their Q3 2026 EPS estimates for Integer in a note issued to investors on Monday, August 24th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings per share of $1.63 for the quarter, down from their prior forecast of $1.68. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Integer’s current full-year earnings is $6.08 per share. Zacks Research also issued estimates for Integer’s Q4 2026 earnings at $1.70 EPS, FY2026 earnings at $6.13 EPS, Q1 2027 earnings at $1.46 EPS, Q2 2027 earnings at $1.61 EPS, Q3 2027 earnings at $1.72 EPS, Q4 2027 earnings at $1.77 EPS, FY2027 earnings at $6.56 EPS, Q1 2028 earnings at $1.71 EPS, Q2 2028 earnings at $1.63 EPS and FY2028 earnings at $6.85 EPS.

A number of other research firms have also recently weighed in on ITGR. Citigroup upped their price objective on shares of Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. HC Wainwright reiterated a “buy” rating on shares of Integer in a research note on Friday, July 24th. Freedom Capital downgraded Integer from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. Wells Fargo & Company increased their price target on Integer from $84.00 to $127.00 and gave the company an “equal weight” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research note on Thursday, June 18th. One analyst has rated the stock with a Buy rating and thirteen have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $109.86.

Integer Stock Performance

Integer stock opened at $124.90 on Tuesday. Integer has a 12-month low of $62.00 and a 12-month high of $126.14. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.73 and a quick ratio of 2.41. The company has a market capitalization of $4.25 billion, a price-to-earnings ratio of 34.12, a price-to-earnings-growth ratio of 2.96 and a beta of 0.61. The firm’s fifty day moving average price is $104.80 and its 200 day moving average price is $93.42.

Integer (NYSE:ITGR) last posted its earnings results on Monday, August 3rd. The medical equipment provider reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.38 by $0.22. The business had revenue of $464.11 million for the quarter, compared to analysts’ expectations of $451.07 million. Integer had a net margin of 6.97% and a return on equity of 12.79%. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.55 earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ITGR. California State Teachers Retirement System increased its position in shares of Integer by 8,977.7% in the 2nd quarter. California State Teachers Retirement System now owns 3,702,956 shares of the medical equipment provider’s stock worth $346,041,000 after purchasing an additional 3,662,164 shares during the last quarter. Bluefin Capital Management LLC lifted its position in shares of Integer by 263.6% during the second quarter. Bluefin Capital Management LLC now owns 30,332 shares of the medical equipment provider’s stock worth $2,835,000 after purchasing an additional 21,990 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Integer during the second quarter worth about $3,292,000. Boussard & Gavaudan Gestion Sas acquired a new position in Integer in the second quarter worth about $2,597,000. Finally, Nantahala Capital Management LLC acquired a new position in Integer in the second quarter worth about $10,401,172,000. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer News Summary

Here are the key news stories impacting Integer this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast to $6.13 from $6.05, while also increasing its Q2 2027 estimate to $1.61 from $1.60 and Q1 2028 estimate to $1.71 from $1.65. These revisions indicate some confidence in Integer’s medium-term earnings trajectory.
• Neutral Sentiment: Zacks maintained a Hold rating on Integer. Its current full-year consensus estimate remains $6.08 per share, while its FY2027 and FY2028 forecasts stand at $6.56 and $6.85, respectively.
• Neutral Sentiment: A law firm announced an opportunity for Integer investors to participate in a reported fraud investigation. The notice does not provide substantive details about the allegations or indicate any confirmed wrongdoing, but such announcements can add uncertainty for shareholders. ITGR Investors Have Opportunity to Join Integer Holdings Corporation Fraud Investigation with SBS Law
• Negative Sentiment: The broader Zacks update was unfavorable: estimates were reduced for Q3 2026 EPS to $1.63 from $1.68, Q4 2026 to $1.70 from $1.77, Q1 2027 to $1.46 from $1.50, Q3 2027 to $1.72 from $1.87, Q4 2027 to $1.77 from $1.90, FY2027 to $6.56 from $6.87, Q2 2028 to $1.63 from $1.74, and FY2028 to $6.85 from $7.20. The cuts suggest analysts see weaker near- to long-term earnings potential than previously expected.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.